Back to today’s briefing

Story perspectives

FDA Grants Rare Disease Designation to Arbor Biotech's ABO-101

2/5/2025

26 5

Summary

Story summary

Arbor Biotechnologies' ABO-101 has received orphan drug and rare pediatric disease designations from the FDA for its potential to treat primary hyperoxaluria type 1, a rare genetic kidney disorder. With a Phase 1/2 clinical trial launching in early 2025, early preclinical results indicate a hopeful reduction in oxalate production, sparking optimism for affected patients.

1 of 1

Story summary

Arbor Biotechnologies' ABO-101 has received orphan drug and rare pediatric disease designations from the FDA for its potential to treat primary hyperoxaluria type 1, a rare genetic kidney disorder. With a Phase 1/2 clinical trial launching in early 2025, early preclinical results indicate a hopeful reduction in oxalate production, sparking optimism for affected patients.